Hellenic Oncology Research Group (HORG), 55 Lomvardou str, 11470 Athens, Greece.
Cancer Chemother Pharmacol. 2012 Jul;70(1):169-76. doi: 10.1007/s00280-012-1901-3. Epub 2012 Jun 6.
To evaluate the efficacy and safety of docetaxel plus capecitabine (DC) combination as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC).
Patients with MBC who had disease progression after initial chemotherapy with anthracyclines (n = 29; 100 %) and taxanes (n = 11; 37.9 %) were treated with oral capecitabine 950 mg/m(2) twice daily on days 1-14 and docetaxel 75 mg/m(2) on day 1 every 3 weeks. Nineteen (65.5 %) patients received this regimen as second line and 10 (34.5 %) as ≥3rd line of therapy. All patients were evaluable for response and toxicity.
Complete response occurred in two (6.9 %) patients and partial response in eleven (37.9 %) for an overall response rate of 44.8 % (95 % CI 26.7-62.9 %). Eleven women (37.9 %) had stable disease and five (17.2 %) progressive disease. Of the eleven patients previously treated with anthracyclines and taxanes, five (45.5 %) responded to DC combination. The median duration of response was 5.7 months (range 3.4-64.2), the median time to disease progression 9.3 months (range 1.2-58), and the median overall survival 25.5 months. No toxic death occurred. Neutropenia grade 4 occurred in 58.6 % of patients and three of them (10.3 %) developed neutropenic fever. Non-hematological toxicities were manageable with grade 3 hand-foot syndrome occurring in 6.9 % of the patients, fatigue in 3.4 %, and neurotoxicity in 3.4 %.
The DC combination is a valuable regimen as salvage treatment in anthracycline- or anthracycline and taxane-pretreated patients with MBC.
评估多西紫杉醇联合卡培他滨（DC）方案作为蒽环类和紫杉类预处理的转移性乳腺癌（MBC）患者解救治疗的疗效和安全性。
MBC 患者在初始化疗中使用蒽环类药物（n=29；100%）和紫杉类药物（n=11；37.9%）后疾病进展，接受卡培他滨 950mg/m²，每天 2 次，第 1-14 天和多西紫杉醇 75mg/m²，第 1 天，每 3 周 1 次。19 例（65.5%）患者作为二线治疗，10 例（34.5%）作为≥3 线治疗。所有患者均对反应和毒性进行评估。
完全缓解 2 例（6.9%），部分缓解 11 例（37.9%），总有效率为 44.8%（95%CI 26.7-62.9%）。11 例患者疾病稳定，5 例（17.2%）疾病进展。11 例既往接受蒽环类和紫杉类药物治疗的患者中，5 例（45.5%）对 DC 联合治疗有反应。中位缓解持续时间为 5.7 个月（范围 3.4-64.2），中位疾病进展时间为 9.3 个月（范围 1.2-58），中位总生存时间为 25.5 个月。无治疗相关死亡。中性粒细胞减少症 4 级发生率为 58.6%，其中 3 例（10.3%）发生中性粒细胞减少性发热。非血液学毒性可耐受，手足综合征 3 级发生率为 6.9%，乏力 3.4%，神经毒性 3.4%。
在蒽环类或蒽环类和紫杉类预处理的 MBC 患者中，DC 联合方案是一种有价值的解救治疗方案。
